Pharma Stock Has Significant Upside Potential, Analyst Says
Research Report
AI Healthcare Co. With 'Bright' Outlook Closes Placement
Biotech Shares Positive Phase I Data for Alzheimer's Treatment
Research Report
Mass. Biotech Shares Strong Q3 Results
Research Report
Boston Biotech Announces Novartis Collaboration
Research Report
Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments
H.C. Wainwright & Co. Raises Price Target on Biotech Following Positive Regulatory Updates
Research Report
Silver Break Out Confirmed
Contributed Opinion
The silver break out is confirmed, and Ron Struthers of Struthers Resource Stock Report expects a move to $50. He explains why he believes Coeur Mining Inc. (CDE:NYSE) offers good value and shares one biotech stock he believes is currently a sell. NY Biopharma Shares Promising Clinical Data
Research Report
Anavex Life Sciences Corp. (AVXL:NASDAQ) recently released encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment, according to an H.C. Wainright & Co. research note. H.C. Wainwright & Co. Shares Buy Rating on Biotech Co.
Research Report
H.C. Wainwright & Co. analysts gave Unicycive Therapeutics Inc. (UNCY:NASDAQ) a Buy rating after the company announced the successful completion of the Phase 1 study for UNI-494 in healthy volunteers. This article is issued on behalf of Treatment.com AI Inc. Is This AI Healthcare Stock Worth Being Overweight On?
Contributed Opinion Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
Mass. Biotech Receives FDA Approval
Research Report
Biofrontera Inc. (BFRI:NASDAQ) receieved FDA's approval of the company's supplemental Biologics License Application (sBLA) to expand the use of Ameluz for treating larger surface areas of actinic keratosis (AK) on the face and scalp, according to a Roth MKM research note. CT Biotech Ready for Clinical Milestones
Research Report
Trevi Therapeutics Inc. (TRVI:NASDAQ) has made progress in its clinical trials for Haduvio, particularly in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients and refractory chronic cough (RCC), according to an EF Hutton research note. Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial
Research Report
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton. New Jersey Biotech Reports Positive Survival Data
Research Report
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price. California Biotech's Target Price 200% Higher Than Current
Research Report
F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients. 
Streetwise Key Charts
